Mesoblast Limited
NASDAQ:MESOBiotechnology
+$0.26 today
- Market cap
- $1.51B
- Beta
- 0.79
- P/E (TTM)
- -23.6
- EPS (TTM)
- -$0.06
Volume 0.13M
Average 0.21M
MESO Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Mesoblast LimitedNASDAQ: MESO
Accounts Receivables · Q4 FY2026 · quarter ended Jun 2026
Accounts receivables growth accelerates
Q4 FY2026 accounts receivables of $7.18M (cash outflow) rose 14.4% year over year, ahead of the -242.9% change in trailing-twelve-month accounts receivables.
Context
- Accounts receivables amounted to 0.0% of revenue in FY2026, down 36.6 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +14.4% holds above the trailing-twelve-month pace of -242.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2026
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 0 | -100.0% |
| FY2025 | 2025-06-30 | 6.29M | +140.7% |
| FY2024 | 2024-06-30 | (15.47M) | -13006.8% |
| FY2023 | 2023-06-30 | (118K) | -184.3% |
| FY2022 | 2022-06-30 | 140K | — |
Accounts Receivables vs competitors
How MESO compares with its peers on the latest reported figures
- MESO's LTM Jun 2026 accounts receivables of $7.18M is the 3rd largest of the 6 companies compared; the peer median is $59.83K.
- Its year-over-year change of -242.9% is the lowest of 6, against a peer median of +279.7%.
- Accounts receivables amounts to 6.0% of revenue for MESO, versus a peer median of 18.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $125.44M | +174128.2% | — | 9.2% | |
| LTM Dec 2025 | $7.55M | +290.3% | — | 28.4% | |
| LTM Jun 2026 | $7.18M | -242.9% | — | 6.0% | |
| LTM Mar 2026 | $1.7M | +279.7% | — | 26.9% | |
| LTM Mar 2026 | $586K | +96.6% | — | 4.0% | |
| LTM Mar 2026 | $59.83K | -100.0% | — | — | |
| Peer median (excluding MESO) | $59.83K | +279.7% | — | 18.1% | |
Competitors are the stored peer set for MESO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Net Income | (91.35M) | (81.89M) | (87.96M) | (102.14M) | 0 |
| Depreciation & Amortization | 4.38M | 4.11M | 4.67M | 6.4M | 0 |
| Deferred Income Tax | (235K) | (212K) | (191K) | 330K | 0 |
| Stock-Based Compensation | 5.54M | 3.66M | 5.87M | 22.09M | 0 |
| Change in Working Capital | 4.87M | (2.47M) | (2.63M) | (3.04M) | 0 |
| Accounts Receivables | 140K | (118K) | (15.47M) | 6.29M | 0 |
| Inventory | 0 | 0 | 0 | 826K | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 4.73M | (2.35M) | 12.84M | (10.16M) | 0 |
| Other Non-Cash Items | 11.02M | 13.54M | 31.78M | 26.41M | (43.83M) |
| Operating Cash Flow | (65.78M) | (63.27M) | (48.46M) | (49.95M) | (43.83M) |
| Capital Expenditures | (232K) | (314K) | (331K) | (730K) | (898K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (125K) |
| Sales of Investments | 0 | 120K | 234K | 241K | 0 |
| Other Investing Activities | (75K) | 120K | (60K) | 559K | (65K) |
| Investing Cash Flow | (232K) | (194K) | (97K) | 120K | (1.02M) |
| Debt Repayment | (6.33M) | (2.66M) | (13.52M) | (9.77M) | (5.94M) |
| Common Stock Issued | 209K | 88.64M | 65.41M | 161.21M | 14.24M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.75M) | (11.48M) | (11.63M) | (4.1M) | (23.64M) |
| Financing Cash Flow | (9.87M) | 74.5M | 40.25M | 147.34M | (15.33M) |
| Effect of Forex Changes | (550K) | (168K) | (55K) | 1.09M | 1.55M |
| Net Change in Cash | (76.43M) | 10.87M | (8.36M) | 98.59M | (58.64M) |
| Free Cash Flow | (66.01M) | (63.58M) | (48.79M) | (50.68M) | (44.73M) |
Mesoblast Limited
NASDAQ:MESO
Intrinsic Alpha fair value
Locked
Current Price
$11.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.